Back to results
US 12,099,056 B2Granted
Reagents, methods, and systems for detecting therapeutic agents to monitor adherence to nucleoside reverse transcriptase inhibitor metabolites
AssigneeOrasure Technologies, Inc.
InventorsGiffin Daughtridge, Keith Kardos, Sharanappa Basappa Rajur, Kim Hwa-Ok, Asharani Dhondiram Kadam
Life of this patent
Estimating the term…
Abstract
The invention provides novel compounds, reagents, systems, and methods for detecting a metabolite related to a NRTI in a biological sample, and uses thereof in monitoring adherence to pre-exposure prophylaxis. Such reagents comprise NRTI derivatives, analogs, NRTI derivatives conjugates, along with antibodies directed to same, which are useful for antibody-based methods, such as a lateral flow immunoassay and other point of care devices.
Claims15
An isolated antibody that specifically binds to tenofovir diphosphate, wherein the antibody comprises one of the sets of variable heavy chain and variable light chain CDR amino acid sequences selected from:
- (A) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 2, 3, and 4, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 6, 7, and 8, respectively;
- (B) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 10, 11, and 12, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 14, 15, and 16, respectively;
- and
- (C) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 18, 19, and 20, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 22, 23, and 24, respectively.
7 more elements
A method for performing a lateral flow assay to determine the presence or absence of tenofovir diphosphate in a fluid sample from a patient, wherein the patient is prescribed or administered a nucleoside reverse transcriptase inhibitor (NRTI) regimen comprising tenofovir, tenofovir disoproxil fumarate, or tenofovir alafenamide, the method comprising the steps:
- (a) applying the fluid sample to a sample pad;
- (b) allowing said sample to flow laterally along the sample pad to a conjugated label pad that is in fluid communication with the sample pad, wherein said conjugated label pad comprises a labeled first reagent specific for tenofovir diphosphate, and wherein a portion of the conjugated label pad and a portion of the sample pad forms a first interface;
- (c) allowing the labeled first reagent to bind tenofovir diphosphate, if present in the fluid sample, to form a labeled first reagent-tenofovir diphosphate complex;
- (d) allowing said sample to flow laterally along the conjugated label pad to a membrane that is in fluid communication with the conjugated label pad, wherein a portion of the membrane and a portion of the conjugated label pad forms a second interface, and wherein said membrane comprises at least one second reagent bound to the membrane to form a test line, and wherein the second reagent is capable of binding to the labeled first reagent;
- (e) allowing the labeled first reagent or, if present, the labeled first reagent-tenofovir diphosphate complex to bind to the second reagent to form a labeled first reagent-second reagent complex at the test line;
- and
- (f) detecting the labeled first reagent-second reagent complex at the test line, if present, as a detectable signal,
- wherein the first reagent is an antibody that specifically binds to tenofovir diphosphate, wherein the antibody comprises one of the sets of variable heavy chain and variable light chain CDR amino acid sequences selected from:
- (i) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 2, 3, and 4, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 6, 7, and 8, respectively;
- (ii) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 10, 11, and 12, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 14, 15, and 16, respectively;
- and
- (iii) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 18, 19, and 20, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 22, 23, and 24, respectively.
15 more elements
A method for performing a lateral flow assay to determine the presence or absence of tenofovir diphosphate in a fluid sample from a patient, wherein the patient is prescribed or administered a nucleoside reverse transcriptase inhibitor (NRTI) regimen comprising tenofovir, tenofovir disoproxil fumarate, or tenofovir alafenamide, the method comprising the steps of:
- (a) applying the fluid sample to a sample pad;
- (b) allowing the fluid sample to flow laterally along the sample pad to a conjugated label pad that is in fluid communication with the sample pad and comprises a labeled first reagent comprising tenofovir diphosphate or a derivative thereof, wherein a portion of the conjugated label pad and a portion of the sample pad forms a first interface;
- (c) allowing the sample to flow laterally along the conjugated label pad to a membrane that is in fluid communication with the conjugated label pad, wherein a portion of the conjugated label pad and a portion of the membrane forms a second interface, wherein the membrane comprises a second reagent specific for tenofovir diphosphate bound to the membrane to form a test line, wherein
- (i) if tenofovir diphosphate is present in the fluid sample, the tenofovir diphosphate is allowed to bind to the second reagent, or
- (ii) if tenofovir diphosphate is absent in the fluid sample, the labeled first reagent is allowed to bind to the second reagent to form a labeled first reagent-second reagent complex at the test line;
- and
- (d) detecting the labeled first reagent-second reagent complex, if formed at the test line, as a detectable signal,
- wherein the second reagent is an antibody that specifically binds to tenofovir diphosphate, wherein the antibody comprises one of the sets of variable heavy chain and variable light chain CDR amino acid sequences selected from:
- (1) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 2, 3, and 4, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 6, 7, and 8, respectively;
- (2) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 10, 11, and 12, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 14, 15, and 16, respectively;
- and
- (3) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 18, 19, and 20, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 22, 23, and 24, respectively.
15 more elements
A device for performing a lateral flow assay to detect tenofovir diphosphate in a fluid sample, the device comprising:
- (a) a sample pad for receiving the fluid sample;
- (b) a conjugated label pad downstream of the sample pad comprising a labeled first reagent specific for tenofovir diphosphate, wherein a portion of the conjugated label pad and a portion of the sample pad form a first interface;
- (c) a membrane downstream of the conjugated label pad, wherein a portion of the membrane and a portion of the conjugated label pad form a second interface;
- and
- (d) at least one second reagent bound to the membrane to form a test line, wherein the second reagent is capable of binding the labeled first reagent,
- wherein the first interface allows fluid to flow from the sample pad to the conjugated label pad and contact the labeled first reagent, and the second interface allows the fluid sample to flow from the conjugated label pad to the membrane and to contact the at least one second reagent to form to a labeled first reagent-second reagent complex as a detectable signal at the test line,
- wherein the first reagent is an antibody that specifically binds to tenofovir diphosphate, wherein the antibody comprises one of the sets of variable heavy chain and variable light chain CDR amino acid sequences selected from:
- (i) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 2, 3, and 4, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 6, 7, and 8, respectively;
- (ii) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 10, 11, and 12, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 14, 15, and 16, respectively;
- and
- (iii) immunoglobulin variable heavy chain CDRs according to SEQ ID NOs:
- 18, 19, and 20, respectively, and immunoglobulin variable light chain CDRs according to SEQ ID NOs:
- 22, 23, and 24, respectively.
14 more elements
Dependencies are inferred from the claim text.